Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 20, 2014 – 11:30 am | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma.  Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.

“Data from a previous randomized Phase 2 trial of ADI-PEG 20 as a monotherapy for the treatment of MPM showed that ADI-PEG 20 significantly reduced risk of progression for patients with mesothelioma,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris. “We hope that ADI-PEG 20 in combination with pemetrexed and cisplatin will provide further benefit to patients in this trial.”

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to systemically deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group is a privately held biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company’s lead therapeutic, ADI-PEG 20, is currently being evaluated in a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris Group is also investigating ADI-PEG 20 as a treatment for other cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, and pancreatic cancer. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO
SOURCE Polaris Group

SGI-DNA Launches Gibson Assembly® HiFi 1 Step Kit for Simple, Seamless and Rapid Construction of Synthetic Genes, Gene Clusters and Genetic Pathways

November 20, 2014 – 11:00 am | Edit Post

LA JOLLA, Calif., Nov. 20, 2014 /PRNewswire/ — SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction.

This is the first high fidelity kit on the market using the Gibson Assembly® method.  Researchers can now assemble up to 5 fragments, including large constructs (up to 100 kb), in a fast, reliable reaction.

“With the Gibson Assembly® HiFi 1 Step Kit researchers can obtain a perfect clone in their initial attempt,” says Vibhu Gupta, Senior Product Manager at SGI-DNA. “The kit provides a proprietary enzyme formulation for Gibson Assembly® that results in significantly less errors at cloning junctions which is a common challenge for researchers in a variety of disciplines.”

A researcher from the University of California, San Diego, Erna van Niekerk, PhD., comments, “I have tried it with a construct and ran a parallel experiment with a competing kit from another vendor. I picked 3 colonies from the Gibson Assembly® HiFi 1 Step Kit and 3 colonies from the competing product. Three of 3 Gibson clones gave me the right insert. Zero of 3 from competing kit gave me the right insert. Of the 3 Gibson clones: 2 of 3 had the correct sequence both forward and reverse sequencing confirmation and 1 of 3 had an extra nucleotide.”

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. It uses a one-step, isothermal approach to enable the rapid assembly of oligonucleotides and multiple DNA fragments. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness and flexibility. This Gibson Assembly® kit provides researchers SGI’s first commercially available option utilizing the Gibson Assembly® method. 

The Gibson Assembly® HiFi 1 Step Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions.

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

SGI-DNA Technical contact: Vibhu Gupta, Senior Product Manager, 858.433.2288; vgupta@syntheticgenomics.com

Media contact: Heather Kowalski, hkowalski@syntheticgenomics.com; 858-361-0466
SOURCE Synthetic Genomics Inc.

SGI-DNA Launches Gibson Assembly® HiFi 1 Step Kit for Simple, Seamless and Rapid Construction of Synthetic Genes, Gene Clusters and Genetic Pathways

November 20, 2014 – 11:00 am | Edit Post

LA JOLLA, Calif., Nov. 20, 2014 /PRNewswire/ — SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction.

This is the first high fidelity kit on the market using the Gibson Assembly® method.  Researchers can now assemble up to 5 fragments, including large constructs (up to 100 kb), in a fast, reliable reaction.

“With the Gibson Assembly® HiFi 1 Step Kit researchers can obtain a perfect clone in their initial attempt,” says Vibhu Gupta, Senior Product Manager at SGI-DNA. “The kit provides a proprietary enzyme formulation for Gibson Assembly® that results in significantly less errors at cloning junctions which is a common challenge for researchers in a variety of disciplines.”

A researcher from the University of California, San Diego, Erna van Niekerk, PhD., comments, “I have tried it with a construct and ran a parallel experiment with a competing kit from another vendor. I picked 3 colonies from the Gibson Assembly® HiFi 1 Step Kit and 3 colonies from the competing product. Three of 3 Gibson clones gave me the right insert. Zero of 3 from competing kit gave me the right insert. Of the 3 Gibson clones: 2 of 3 had the correct sequence both forward and reverse sequencing confirmation and 1 of 3 had an extra nucleotide.”

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. It uses a one-step, isothermal approach to enable the rapid assembly of oligonucleotides and multiple DNA fragments. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness and flexibility. This Gibson Assembly® kit provides researchers SGI’s first commercially available option utilizing the Gibson Assembly® method. 

The Gibson Assembly® HiFi 1 Step Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions.

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

SGI-DNA Technical contact: Vibhu Gupta, Senior Product Manager, 858.433.2288; vgupta@syntheticgenomics.com

Media contact: Heather Kowalski, hkowalski@syntheticgenomics.com; 858-361-0466
SOURCE Synthetic Genomics Inc.

SGI-DNA Launches Gibson Assembly® HiFi 1 Step Kit for Simple, Seamless and Rapid Construction of Synthetic Genes, Gene Clusters and Genetic Pathways

November 20, 2014 – 11:00 am | Edit Post

LA JOLLA, Calif., Nov. 20, 2014 /PRNewswire/ — SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction.

This is the first high fidelity kit on the market using the Gibson Assembly® method.  Researchers can now assemble up to 5 fragments, including large constructs (up to 100 kb), in a fast, reliable reaction.

“With the Gibson Assembly® HiFi 1 Step Kit researchers can obtain a perfect clone in their initial attempt,” says Vibhu Gupta, Senior Product Manager at SGI-DNA. “The kit provides a proprietary enzyme formulation for Gibson Assembly® that results in significantly less errors at cloning junctions which is a common challenge for researchers in a variety of disciplines.”

A researcher from the University of California, San Diego, Erna van Niekerk, PhD., comments, “I have tried it with a construct and ran a parallel experiment with a competing kit from another vendor. I picked 3 colonies from the Gibson Assembly® HiFi 1 Step Kit and 3 colonies from the competing product. Three of 3 Gibson clones gave me the right insert. Zero of 3 from competing kit gave me the right insert. Of the 3 Gibson clones: 2 of 3 had the correct sequence both forward and reverse sequencing confirmation and 1 of 3 had an extra nucleotide.”

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. It uses a one-step, isothermal approach to enable the rapid assembly of oligonucleotides and multiple DNA fragments. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness and flexibility. This Gibson Assembly® kit provides researchers SGI’s first commercially available option utilizing the Gibson Assembly® method. 

The Gibson Assembly® HiFi 1 Step Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions.

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

SGI-DNA Technical contact: Vibhu Gupta, Senior Product Manager, 858.433.2288; vgupta@syntheticgenomics.com

Media contact: Heather Kowalski, hkowalski@syntheticgenomics.com; 858-361-0466
SOURCE Synthetic Genomics Inc.

SGI-DNA Launches Gibson Assembly® HiFi 1 Step Kit for Simple, Seamless and Rapid Construction of Synthetic Genes, Gene Clusters and Genetic Pathways

November 20, 2014 – 11:00 am | Edit Post

LA JOLLA, Calif., Nov. 20, 2014 /PRNewswire/ — SGI-DNA announces the launch of the Gibson Assembly® HiFi 1 Step Kit which allows researchers to assemble multiple, large DNA fragments in a simple one hour, one-step reaction.

This is the first high fidelity kit on the market using the Gibson Assembly® method.  Researchers can now assemble up to 5 fragments, including large constructs (up to 100 kb), in a fast, reliable reaction.

“With the Gibson Assembly® HiFi 1 Step Kit researchers can obtain a perfect clone in their initial attempt,” says Vibhu Gupta, Senior Product Manager at SGI-DNA. “The kit provides a proprietary enzyme formulation for Gibson Assembly® that results in significantly less errors at cloning junctions which is a common challenge for researchers in a variety of disciplines.”

A researcher from the University of California, San Diego, Erna van Niekerk, PhD., comments, “I have tried it with a construct and ran a parallel experiment with a competing kit from another vendor. I picked 3 colonies from the Gibson Assembly® HiFi 1 Step Kit and 3 colonies from the competing product. Three of 3 Gibson clones gave me the right insert. Zero of 3 from competing kit gave me the right insert. Of the 3 Gibson clones: 2 of 3 had the correct sequence both forward and reverse sequencing confirmation and 1 of 3 had an extra nucleotide.”

The Gibson Assembly® method was developed in 2009 by Dan Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team’s quest to construct the first synthetic cell. It uses a one-step, isothermal approach to enable the rapid assembly of oligonucleotides and multiple DNA fragments. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness and flexibility. This Gibson Assembly® kit provides researchers SGI’s first commercially available option utilizing the Gibson Assembly® method. 

The Gibson Assembly® HiFi 1 Step Kit is available in 3 sizes: 5 reactions (starter kit), 10 reactions and 50 reactions.

For more information on the Gibson Assembly® HiFi 1 Step Kit, please visit www.sgidna.com

All products are intended for research use only. Not intended for diagnostic uses.

The Gibson Assembly® method is also available under commercial license. For more information contact us at info@sgidna.com

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.

SGI-DNA Technical contact: Vibhu Gupta, Senior Product Manager, 858.433.2288; vgupta@syntheticgenomics.com

Media contact: Heather Kowalski, hkowalski@syntheticgenomics.com; 858-361-0466
SOURCE Synthetic Genomics Inc.

Signaling Molecule Crucial to Stem Cell Reprogramming

November 20, 2014 – 10:54 am | Edit Post

While investigating a rare genetic disorder, researchers at the University of California, San Diego School of Medicine have discovered that a ubiquitous signaling molecule is crucial to cellular reprogramming, a finding with significant implications for stem cell-based regenerative medicine, wound repair therapies and potential cancer treatments.

Company tackling love handles goes public

November 20, 2014 – 10:05 am | Edit Post

Neothetics, a developer of cosmetic therapies, said it will sell 4.65 million shares at $14 apiece.